Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)

Overview

This study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral ibrexafungerp (formerly "SCY-078") compared to placebo in female subjects 12 years and older with recurrent VVC (RVVC).

Full Title of Study: “A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) Compared to Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: September 1, 2021

Detailed Description

This study is a Phase 3, multicenter, randomized, double-blind study to evaluate the efficacy and safety of oral ibrexafungerp (formerly "SCY-078") compared to placebo in female subjects 12 years and older with RVVC. The primary objective of the study is to evaluate the efficacy of oral ibrexafungerp in preventing recurrences of VVC in subjects with RVVC based on Clinical Success. Approximately 320 subjects are planned to be enrolled into the study. All subjects will receive treatment with oral fluconazole for their acute episode present at screening. Subjects who respond to fluconazole for their acute episode will be enrolled in the prevention of recurrence phase of the study and randomized to ibrexafungerp or placebo. Subjects who fail treatment with fluconazole for their acute episode will be included in a nested open label Sub-Study, in which they will be offered one-day oral ibrexafungerp for their unresolved acute episode.

Interventions

  • Drug: Fluconazole Tablet
    • 150 mg every 72 hours for 3 doses
  • Drug: IBREXAFUNGERP
    • 300 mg BID (one day) every 4 weeks for a total of 6 dosing days
  • Drug: Placebo oral tablet
    • BID (one day) every 4 weeks for a total of 6 dosing days

Arms, Groups and Cohorts

  • Experimental: Ibrexafungerp
    • Oral Fluconazole 150 mg every 72 hours for 3 doses followed by Oral Ibrexafungerp 300 mg BID (one day) every 4 weeks for a total of 6 dosing days
  • Placebo Comparator: Placebo
    • Oral Fluconazole 150 mg every 72 hours for 3 doses followed by Oral Placebo BID (one day) every 4 weeks for a total of 6 dosing days

Clinical Trial Outcome Measures

Primary Measures

  • Clinical Success
    • Time Frame: Week 24
    • Efficacy as measured by the percentage of subjects with documented Clinical Success.

Secondary Measures

  • The Percentage of Subjects With no Mycologically Proven Recurrence
    • Time Frame: Week 24
    • Efficacy as measured by the percentage of subjects with no Mycologically Proven Recurrence
  • Safety and Tolerability
    • Time Frame: Week 24
    • Safety as measured by the number of subjects who discontinue due to treatment related adverse events.

Participating in This Clinical Trial

Key Inclusion Criteria:

  • Diagnosis of symptomatic VVC with microscopic examination with KOH positive for yeast and normal vaginal pH. – History of 3 or more episodes of VVC in the past 12 months. – Culture confirmation and resolution of the signs and symptoms of the initial VVC episode (with treatment). – Able to take oral tablets and capsules. Key exclusion Criteria:

  • Vaginal conditions other than recurrent VVC that may interfere with the diagnosis or evaluation of response to therapy. – Recent use of systemic and/or topical vaginal antifungal products. – Pregnant. – History of major system organ disease.

Gender Eligibility: Female

Minimum Age: 12 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Scynexis, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Nkechi Azie, MD, Study Director, Scynexis, Inc.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.